# II. Diseases

## Solid Tumors

- [ ] Hepatocellular carcinoma (HCC)
- [ ] Breast cancer
- [ ] Lung cancer
- [ ] Colorectal cancer
- [ ] Prostate cancer
- [ ] Ovarian carcinoma
- [ ] Cervical cancer
- [ ] Glioma
- [ ] Adult high-grade glioma
- [ ] Head and neck squamous cell carcinoma
- [ ] Lung adenocarcinoma
- [ ] Stomach cancer
- [ ] Kidney cancer
- [ ] Liver cancer

## Hematological Malignancies

- [ ] Acute lymphoblastic leukemia
- [ ] Chronic lymphocytic leukemia

## Non-Neoplastic Diseases

- [ ] Tuberculosis
- [ ] Allergic rhinitis
- [ ] Autoimmune diseases
- [ ] Hepatitis

---

# III. Immune Cells

## Lymphoid Lineage

- [ ] CD4⁺ T cells
- [ ] CD8⁺ T cells
- [ ] Cytotoxic T lymphocytes (CTLs)
- [ ] Regulatory T cells (Tregs)
- [ ] Natural killer (NK) cells
- [ ] Pro-B cells

## Myeloid Lineage

- [ ] Dendritic cells (DCs)
- [ ] Macrophages
- [ ] Monocytes
- [ ] Neutrophils
- [ ] Myeloid-derived suppressor cells (MDSCs)

---

# IV. Immune Checkpoints

- [ ] CTLA-4
- [ ] PD-1
- [ ] PD-L1
- [ ] PD-L2
- [ ] HLA-G
- [ ] IDO1

Alternate Names:

- [ ] CD279
- [ ] CD274
- [ ] B7-H1
- [ ] B7-DC

---

# V. Cytokines & Immune Mediators

- [ ] IL-1
- [ ] IL-2
- [ ] IL-6
- [ ] IL-10
- [ ] IL-12
- [ ] IFN-γ
- [ ] TNF-α
- [ ] TGF-β
- [ ] VEGF
- [ ] CCL5 (RANTES)

---

# VI. Immune Receptors & Surface Markers

## Co-stimulatory Molecules

- [ ] CD28
- [ ] CD80
- [ ] CD86

## Antigen Presentation

- [ ] MHC Class I
- [ ] MHC Class II
- [ ] tsMHC-II

## Pattern Recognition Receptors

- [ ] TLR2
- [ ] TLR3
- [ ] TLR4
- [ ] TLR7
- [ ] TLR8
- [ ] TLR9
- [ ] RIG-I
- [ ] NOD1
- [ ] NOD2
- [ ] NLR

## Other Receptors

- [ ] TCR
- [ ] BCR
- [ ] NKG2D
- [ ] FZD (Frizzled receptor)
- [ ] CCR5

---

# VII. Tumor Antigens

## Glycoproteins

- [ ] Glypican-3 (GPC3)
- [ ] Mucin-1 (MUC1)

## Heat Shock Proteins

- [ ] HSP27
- [ ] HSP40
- [ ] HSP70
- [ ] HSP90
- [ ] HSPPC96
- [ ] GP96

## Oncoproteins

- [ ] Metadherin (MTDH / AEG-1 / LYRIC)

---

# VIII. Genes

- [ ] PDCD1
- [ ] CD274
- [ ] PDCD1LG2
- [ ] MUC1
- [ ] MTDH
- [ ] BRAF
- [ ] c-MYC
- [ ] GSK3β
- [ ] LEF-1

---

# IX. Signaling Pathways

- [ ] MAPK pathway
- [ ] Ras–Raf–MEK–ERK cascade
- [ ] PI3K/Akt pathway
- [ ] NF-κB pathway
- [ ] JAK–STAT pathway
- [ ] Wnt/β-catenin pathway
- [ ] Hippo pathway
- [ ] HIF pathway

---

# X. Biological Processes

## Immune Processes

- [ ] Antigen presentation
- [ ] Immune surveillance
- [ ] Immune evasion
- [ ] Cytokine secretion

## Tumor Biology

- [ ] Carcinogenesis
- [ ] Tumor proliferation
- [ ] Metastasis
- [ ] Angiogenesis
- [ ] Apoptosis
- [ ] Epithelial–mesenchymal transition (EMT)

## Epigenetic Regulation

- [ ] DNA methylation
- [ ] Histone modification

---

# XI. Therapeutic Modalities

## Checkpoint Inhibitors

- [ ] Anti-PD-1 therapy
- [ ] Anti-PD-L1 therapy
- [ ] Anti-CTLA-4 therapy

## Monoclonal Antibodies

- [ ] GC33
- [ ] YP7
- [ ] hYP7
- [ ] HN3
- [ ] HS20

## Other Immunotherapies

- [ ] CAR T-cell therapy
- [ ] Dendritic cell–based vaccine
- [ ] DNA vaccine
- [ ] Vaccinia virus vaccine
- [ ] Cytokine therapy
- [ ] Radio-immunotherapy
- [ ] Oncolytic virus therapy
- [ ] Biological response modifier (BRM) therapy

---

## Small-Molecule Inhibitors

- [ ] Trametinib
- [ ] Selumetinib
- [ ] G-38963
- [ ] BVD-523

---

# XII. Vaccines & Adjuvants

- [ ] Bacillus Calmette–Guérin (BCG)
- [ ] Mannan
- [ ] Keyhole limpet hemocyanin
- [ ] Freund’s adjuvant
- [ ] Saponin

---

# XIII. Tumor Microenvironment

- [ ] Tumor microenvironment (TME)
- [ ] Immunosuppressive cytokines
- [ ] Immune checkpoint upregulation
- [ ] Suppressive immune cells (Tregs, MDSCs)
